Developer docs
API playgroundTry for free, no card

Search company profiles

Amarin

Full company profile

uuid00098ty

Namestring
Amarin
Legal namestring
Amarin Corporation plc
Websiteurl
amarincorp.com
Company typeenum
Public
Founded yearint
1989
Descriptiontext

Amarin Corporation plc is an Ireland-domiciled, NASDAQ-listed (AMRN) biopharmaceutical company founded in 1989 that develops and commercializes VASCEPA/VAZKEPA (icosapent ethyl) — the first FDA-approved prescription therapy comprised solely of icosapent ethyl, a proprietary high-purity form of the omega-3 fatty acid eicosapentaenoic acid (EPA) derived from fish oil. The product is indicated for cardiovascular risk reduction as an adjunct to maximally tolerated statin therapy in adult patients with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease or diabetes with additional risk factors, and is also approved for severe hypertriglyceridemia (≥500 mg/dL). Its clinical and commercial foundation is the landmark REDUCE-IT cardiovascular outcomes trial (8,179 patients, 400+ sites across 11 countries, ~4.9-year median follow-up) demonstrating a 25% reduction in major adverse cardiovascular events when added to statin therapy, supported by 500+ scientific publications and 70+ medical society recommendations. Regulatory approvals span 50+ countries with European IP protection extending to 2039.

Amarin operates a hybrid commercialization model. In the United States, a direct sales organization markets VASCEPA to cardiologists and high-prescribing physicians through national pharmacy benefit managers (generating $35.6M of Q1 2026 revenue, ~79% of total). Internationally, the company executes a fully-partnered distribution strategy covering approximately 100 markets via exclusive licensing and supply agreements with Recordati S.p.A. (Europe, June 2025 deal, 59 countries, $25M upfront), Eddingpharm (China, 2015, approved 2024), HLS Therapeutics (Canada, 2017), Lotus Pharmaceuticals (SE Asia/South Korea, 2023), Neopharm (Israel, 2023), and Vianex (Greece, 2024). Revenue streams include U.S. product sales, European product sales ($4.9M in Q1 2026), Rest-of-World product sales ($2.8M), and licensing/royalty income ($1.8M, up 84% YoY).

Following a global restructuring initiative targeting $70M in annualized savings ($39.6M realized through Q1 2026), Amarin reported two consecutive quarters of positive operating cash flow, holds $307.8M in cash and investments with no debt, and is exploring strategic alternatives with Barclays. Reported FY 2025 revenue of $213.6M (down 6.5% YoY) reflects ongoing U.S. pressure from generic competition, which was materially compounded by the June 2026 U.S. Supreme Court ruling in Hikma v. Amarin that Hikma's skinny-label generic icosapent ethyl does not infringe Amarin's patents.

Short descriptiontext

Amarin Corporation plc is an Ireland-domiciled biopharmaceutical company that develops and commercializes VASCEPA/VAZKEPA (icosapent ethyl), the first FDA-approved prescription EPA therapy for cardiovascular risk reduction in statin-treated patients with elevated triglycerides, sold via direct U.S. sales and partner networks across ~100 global markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBallsbridge, Ireland
HQ citystring
Ballsbridge
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular pharmaceuticals, prescription omega-3 therapy, cardiovascular risk reduction, lipid management drugs, icosapent ethyl treatment
Industry2 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYAFAJAKAC
Omega-3 & Specialty Lipids (Fish/Algal Oils, EPA/DHA, MCTs, CLA, Phospholipids)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cardiovascular Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales - United States
TypeOthers
Description

Direct sales of VASCEPA in the U.S. market through Amarin's commercial organization. Revenue from national pharmacy benefit managers (PBMs) and direct prescriptions. Q1 2026 U.S. product revenue of $35.6 million.

amarincorp.com
2Product Revenue - Europe
TypeOthers
Description

Revenue from VAZKEPA sales through European partners, particularly Recordati S.p.A. under exclusive licensing and supply agreement. Q1 2026 European product revenue of $4.9 million.

amarincorp.com
3Licensing and Royalties
TypeLicensing Royalties
Description

Revenue from international commercial partners including royalties from Eddingpharm (China), HLS Therapeutics (Canada), Lotus Pharmaceuticals (Southeast Asia), and other partners. Q1 2026 licensing and royalty revenue of $1.8 million, up 84% year-over-year.

amarincorp.com
4Product Revenue - Rest of World
TypeOthers
Description

Revenue from international markets including Canada, China, Australia, Lebanon, UAE, Saudi Arabia, Qatar, Bahrain, and Kuwait. Q1 2026 ROW product revenue of $2.8 million.

amarincorp.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1VASCEPA/VAZKEPA (icosapent ethyl)
Description

Prescription cardiovascular drug (icosapent ethyl capsules) approved for reducing cardiovascular risk in high-risk patients with elevated triglycerides on statin therapy. Also approved for severe hypertriglyceridemia. Marketed as VASCEPA in the US and VAZKEPA in Europe and other markets.

amarincorp.com
+1 more record
Core offering1 text field

Amarin develops, manufactures, and commercializes VASCEPA/VAZKEPA (icosapent ethyl), a prescription-only omega-3 fatty acid (EPA) therapy approved as an adjunct to statin therapy to reduce cardiovascular events in high-risk patients with elevated triglycerides, and as adjunct to diet for severe hypertriglyceridemia. The company sells directly in the U.S. and through regional commercial partners across approximately 100 international markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 25% reduction in major adverse cardiovascular events (MACE) compared to placebo when added to statin therapy
+5 more records
Product overview1 text field

Amarin is a global pharmaceutical company with a single commercialized product - VASCEPA®/VAZKEPA® (icosapent ethyl). This is a unified product marketed under different brand names in different regions: VASCEPA® in the United States and other markets, and VAZKEPA® in Europe and the UK. The product is a prescription-only fish oil-derived medication (icosapent ethyl/EPA) approved for cardiovascular risk reduction in statin-treated patients with elevated triglycerides and for severe hypertriglyceridemia. The company operates through direct sales in the U.S. and indirect distribution internationally through commercial partners, covering approximately 100 markets worldwide.

Product and service1 record
1VASCEPA/VAZKEPA (icosapent ethyl)
CategoryCardiovascular prescription drug
Description

Prescription-only medicine containing icosapent ethyl, a unique form of EPA (an omega-3 fatty acid derived from fish oil). Marketed as VASCEPA in the U.S. and VAZKEPA in Europe and other markets. Approved as an adjunct to maximally tolerated statin therapy to reduce cardiovascular risk in adult patients with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease or diabetes plus additional risk factors; and as adjunct to diet to reduce triglyceride levels in patients with severe hypertriglyceridemia (≥500 mg/dL). Prescribed more than 25 million times globally.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-01
Description

Exclusive license and supply agreement with Recordati S.p.A. to commercialize VAZKEPA in Europe. Recordati is a leading international pharmaceutical group with consolidated net revenues of €2.6 billion in 2025. Recordati commenced commercial efforts in 10 countries including Italy (Q4 2025 launch) with plans to expand across Europe over several years. This partnership represents Amarin's fully-partnered international commercial strategy.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Partnership with Vianex for distribution and commercialization of VAZKEPA in Greece. Reimbursement secured in Greece in 2024.

3Lotus Pharmaceuticals
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-01
Description

Exclusive long-term agreement to distribute and commercialize VAZKEPA across ten countries in Southeast Asia and South Korea, announced in 2023.

amarincorp.com
4Neopharm
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-01
Description

Exclusive marketing and commercial agreement for VAZKEPA in Israel, announced in 2023. VAZKEPA approved in Israel in 2023.

amarincorp.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-01-01
Description

Agreement to commercialize VASCEPA in Canada, announced in 2017. HLS Therapeutics presents REDUCE-IT and EPA mechanistic data at Canadian Cardiovascular Congress and commercializes VASCEPA in Canada.

6Eddingpharm
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2015-01-01
Description

Agreement to develop and commercialize VASCEPA in China, announced in 2015. EddingPharm received regulatory approval for VASCEPA in mainland China for the cardiovascular risk reduction indication in 2024.

amarincorp.com
7Biologi
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional commercial partner for Australia. Biologi is listed among Amarin's trusted strategic partners.

amarincorp.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional commercial partner for Australia. CSL Seqirus is listed among Amarin's trusted strategic partners.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner for REDUCE-IT trial. Dr. Deepak L. Bhatt serves as Chair of the REDUCE-IT Steering Committee with research funding paid to Brigham and Women's Hospital and the Icahn School of Medicine at Mount Sinai.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner for REDUCE-IT trial. Dr. Deepak L. Bhatt is Director of the Mount Sinai Fuster Heart Hospital and Principal Investigator of REDUCE-IT. Research funding paid to Icahn School of Medicine at Mount Sinai.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty pharma focused on lipid management with NEXLETOL/NEXLIZET (bempedoic acid) for LDL-C lowering in statin-treated patients. Targets the same cardiovascular residual-risk patient population as Amarin, with overlapping cardiology prescribers and similar commercial dynamics.

TypeDirect peer
Description

Develops olezarsen (TRYNGOLZA) for familial chylomicronemia syndrome and severe hypertriglyceridemia — directly competing with VASCEPA in one of its approved indications. Ionis/AstraZeneca partnership provides commercial scale that Amarin lacks in international markets.

TypeEmerging player
Description

Late-stage clinical biotech developing obicetrapib, an oral CETP inhibitor for dyslipidemia. Targeting statin-treated patients with elevated CV risk — directly overlapping with Amarin's prescriber base and patient population in CV risk reduction.

TypeEmerging player
Description

Clinical-stage company developing RNA interference therapeutics for cardiovascular and metabolic diseases, including plozasiran (APOC3) targeting severe hypertriglyceridemia. Competes in the same triglyceride-driven CV space as icosapent ethyl.

TypeEmerging player
Description

Specialty pharma with Rezdiffra (resmetirom) approved for MASH/NASH with significant fibrosis. Cardiovascular/metabolic specialty focus with overlapping physician call points in endocrinology and cardiology practices.

TypeBroad incumbent
Description

Global biopharmaceutical incumbent with Repatha (evolocumab), a leading PCSK9 inhibitor for LDL-C lowering. Competes with Amarin in cardiovascular lipid management through different mechanism but overlapping prescriber base and patient population.

TypeBroad incumbent
Description

Large incumbent with Leqvio (inclisiran), an siRNA therapy for LDL-C lowering in cardiovascular patients. Represents a meaningful alternative therapeutic approach in the lipid management space where Amarin competes for prescriber attention and guideline inclusion.

TypeBroad incumbent
Description

Global pharma incumbent with Praluent (alirocumab, partnered with Regeneron), a PCSK9 inhibitor. Competes in cardiovascular lipid management with established cardiology commercial infrastructure across all major markets including Europe and Asia.

TypeBroad incumbent
Description

Largest pharmaceutical incumbent with legacy Lipitor franchise and broader cardiovascular portfolio. Provides scale benchmark and potential acquirer profile, while competing in the broader lipid management and CV risk reduction market.

TypeEmerging player
Description

Clinical-stage biotech developing metabolic and cardiovascular therapies, including VK2735 for obesity and oral formulations targeting cardiometabolic disease. Emerging competitor in adjacent CV/metabolic therapeutic categories.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amarin

Cardiovascular Pharmaceuticalsamarincorp.com

Amarin Corporation plc is an Ireland-domiciled biopharmaceutical company that develops and commercializes VASCEPA/VAZKEPA (icosapent ethyl), the first FDA-approved prescription EPA therapy for cardiovascular risk reduction in statin-treated patients with elevated triglycerides, sold via direct U.S. sales and partner networks across ~100 global markets.

What Amarin does

Amarin Corporation plc is an Ireland-domiciled, NASDAQ-listed (AMRN) biopharmaceutical company founded in 1989 that develops and commercializes VASCEPA/VAZKEPA (icosapent ethyl) — the first FDA-approved prescription therapy comprised solely of icosapent ethyl, a proprietary high-purity form of the omega-3 fatty acid eicosapentaenoic acid (EPA) derived from fish oil. The product is indicated for cardiovascular risk reduction as an adjunct to maximally tolerated statin therapy in adult patients with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease or diabetes with additional risk factors, and is also approved for severe hypertriglyceridemia (≥500 mg/dL). Its clinical and commercial foundation is the landmark REDUCE-IT cardiovascular outcomes trial (8,179 patients, 400+ sites across 11 countries, ~4.9-year median follow-up) demonstrating a 25% reduction in major adverse cardiovascular events when added to statin therapy, supported by 500+ scientific publications and 70+ medical society recommendations. Regulatory approvals span 50+ countries with European IP protection extending to 2039.

Amarin operates a hybrid commercialization model. In the United States, a direct sales organization markets VASCEPA to cardiologists and high-prescribing physicians through national pharmacy benefit managers (generating $35.6M of Q1 2026 revenue, ~79% of total). Internationally, the company executes a fully-partnered distribution strategy covering approximately 100 markets via exclusive licensing and supply agreements with Recordati S.p.A. (Europe, June 2025 deal, 59 countries, $25M upfront), Eddingpharm (China, 2015, approved 2024), HLS Therapeutics (Canada, 2017), Lotus Pharmaceuticals (SE Asia/South Korea, 2023), Neopharm (Israel, 2023), and Vianex (Greece, 2024). Revenue streams include U.S. product sales, European product sales ($4.9M in Q1 2026), Rest-of-World product sales ($2.8M), and licensing/royalty income ($1.8M, up 84% YoY).

Following a global restructuring initiative targeting $70M in annualized savings ($39.6M realized through Q1 2026), Amarin reported two consecutive quarters of positive operating cash flow, holds $307.8M in cash and investments with no debt, and is exploring strategic alternatives with Barclays. Reported FY 2025 revenue of $213.6M (down 6.5% YoY) reflects ongoing U.S. pressure from generic competition, which was materially compounded by the June 2026 U.S. Supreme Court ruling in Hikma v. Amarin that Hikma's skinny-label generic icosapent ethyl does not infringe Amarin's patents.

Amarin firmographics

Firmographics
Name
Amarin
Legal name
Amarin Corporation plc
Website
https://amarincorp.com
Company type
Public
Founded year
1989
Operating status
Operating
Headcount range
251–500 employees
Short description
Amarin Corporation plc is an Ireland-domiciled biopharmaceutical company that develops and commercializes VASCEPA/VAZKEPA (icosapent ethyl), the first FDA-approved prescription EPA therapy for cardiovascular risk reduction in statin-treated patients with elevated triglycerides, sold via direct U.S. sales and partner networks across ~100 global markets.
Ownership category
akta.pro rank

Amarin industry classification

Industry
Product category
Cardiovascular Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYAFAJAKAC
Omega-3 & Specialty Lipids (Fish/Algal Oils, EPA/DHA, MCTs, CLA, Phospholipids)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

Keywords

  • Cardiovascular pharmaceuticals
  • Prescription omega-3 therapy
  • Cardiovascular risk reduction
  • Lipid management drugs
  • Icosapent ethyl treatment

Where Amarin is headquartered

Location

Headquarters

HQ city
Ballsbridge
HQ country
Ireland
HQ region
Europe

Offices3 records

Markets served

Amarin business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain

Revenue model

  1. Product Sales - United States: Direct sales of VASCEPA in the U.S. market through Amarin's commercial organization. Revenue from national pharmacy benefit managers (PBMs) and direct prescriptions. Q1 2026 U.S. product revenue of $35.6 million.
  2. Product Revenue - Europe: Revenue from VAZKEPA sales through European partners, particularly Recordati S.p.A. under exclusive licensing and supply agreement. Q1 2026 European product revenue of $4.9 million.
  3. Licensing and Royalties: Revenue from international commercial partners including royalties from Eddingpharm (China), HLS Therapeutics (Canada), Lotus Pharmaceuticals (Southeast Asia), and other partners. Q1 2026 licensing and royalty revenue of $1.8 million, up 84% year-over-year.
  4. Product Revenue - Rest of World: Revenue from international markets including Canada, China, Australia, Lebanon, UAE, Saudi Arabia, Qatar, Bahrain, and Kuwait. Q1 2026 ROW product revenue of $2.8 million.

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Amarin product offering

Product offering

Core offering

Amarin develops, manufactures, and commercializes VASCEPA/VAZKEPA (icosapent ethyl), a prescription-only omega-3 fatty acid (EPA) therapy approved as an adjunct to statin therapy to reduce cardiovascular events in high-risk patients with elevated triglycerides, and as adjunct to diet for severe hypertriglyceridemia. The company sells directly in the U.S. and through regional commercial partners across approximately 100 international markets.

Product overview

Amarin is a global pharmaceutical company with a single commercialized product - VASCEPA®/VAZKEPA® (icosapent ethyl). This is a unified product marketed under different brand names in different regions: VASCEPA® in the United States and other markets, and VAZKEPA® in Europe and the UK. The product is a prescription-only fish oil-derived medication (icosapent ethyl/EPA) approved for cardiovascular risk reduction in statin-treated patients with elevated triglycerides and for severe hypertriglyceridemia. The company operates through direct sales in the U.S. and indirect distribution internationally through commercial partners, covering approximately 100 markets worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • VASCEPA/VAZKEPA (icosapent ethyl): Prescription cardiovascular drug (icosapent ethyl capsules) approved for reducing cardiovascular risk in high-risk patients with elevated triglycerides on statin therapy. Also approved for severe hypertriglyceridemia. Marketed as VASCEPA in the US and VAZKEPA in Europe and other markets.
  • REDUCE-IT

Products and services

  • VASCEPA/VAZKEPA (icosapent ethyl) Prescription-only medicine containing icosapent ethyl, a unique form of EPA (an omega-3 fatty acid derived from fish oil). Marketed as VASCEPA in the U.S. and VAZKEPA in Europe and other markets. Approved as an adjunct to maximally tolerated statin therapy to reduce cardiovascular risk in adult patients with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease or diabetes plus additional risk factors; and as adjunct to diet to reduce triglyceride levels in patients with severe hypertriglyceridemia (≥500 mg/dL). Prescribed more than 25 million times globally.

Quantifiable outcome

  • 25% reduction in major adverse cardiovascular events (MACE) compared to placebo when added to statin therapy
  • +5 more outcomes

Companies that use Amarin

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Amarin technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Amarin partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, minor and major.

  • Recordati S.p.A.coreChannel Partner/ Reseller/ Distributor · 1 June 2025Exclusive license and supply agreement with Recordati S.p.A. to commercialize VAZKEPA in Europe. Recordati is a leading international pharmaceutical group with consolidated net revenues of €2.6 billion in 2025. Recordati commenced commercial efforts in 10 countries including Italy (Q4 2025 launch) with plans to expand across Europe over several years. This partnership represents Amarin's fully-partnered international commercial strategy.
  • VianexminorChannel Partner/ Reseller/ Distributor · 1 January 2024Partnership with Vianex for distribution and commercialization of VAZKEPA in Greece. Reimbursement secured in Greece in 2024.
  • Lotus PharmaceuticalsmajorChannel Partner/ Reseller/ Distributor · 1 January 2023Exclusive long-term agreement to distribute and commercialize VAZKEPA across ten countries in Southeast Asia and South Korea, announced in 2023.
  • NeopharmmajorChannel Partner/ Reseller/ Distributor · 1 January 2023Exclusive marketing and commercial agreement for VAZKEPA in Israel, announced in 2023. VAZKEPA approved in Israel in 2023.
  • HLS TherapeuticscoreChannel Partner/ Reseller/ Distributor · 1 January 2017Agreement to commercialize VASCEPA in Canada, announced in 2017. HLS Therapeutics presents REDUCE-IT and EPA mechanistic data at Canadian Cardiovascular Congress and commercializes VASCEPA in Canada.
  • EddingpharmcoreChannel Partner/ Reseller/ Distributor · 1 January 2015Agreement to develop and commercialize VASCEPA in China, announced in 2015. EddingPharm received regulatory approval for VASCEPA in mainland China for the cardiovascular risk reduction indication in 2024.
  • BiologiminorChannel Partner/ Reseller/ DistributorRegional commercial partner for Australia. Biologi is listed among Amarin's trusted strategic partners.
  • CSL SeqirusminorChannel Partner/ Reseller/ DistributorRegional commercial partner for Australia. CSL Seqirus is listed among Amarin's trusted strategic partners.
  • Brigham and Women's HospitalcoreStrategic or Co-development PartnerResearch partner for REDUCE-IT trial. Dr. Deepak L. Bhatt serves as Chair of the REDUCE-IT Steering Committee with research funding paid to Brigham and Women's Hospital and the Icahn School of Medicine at Mount Sinai.
  • Mount Sinai - Icahn School of MedicinecoreStrategic or Co-development PartnerAcademic partner for REDUCE-IT trial. Dr. Deepak L. Bhatt is Director of the Mount Sinai Fuster Heart Hospital and Principal Investigator of REDUCE-IT. Research funding paid to Icahn School of Medicine at Mount Sinai.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Amarin competitors and assessment

Company assessment

Direct peers

  • Esperion Therapeutics: Specialty pharma focused on lipid management with NEXLETOL/NEXLIZET (bempedoic acid) for LDL-C lowering in statin-treated patients. Targets the same cardiovascular residual-risk patient population as Amarin, with overlapping cardiology prescribers and similar commercial dynamics.
  • Ionis Pharmaceuticals: Develops olezarsen (TRYNGOLZA) for familial chylomicronemia syndrome and severe hypertriglyceridemia — directly competing with VASCEPA in one of its approved indications. Ionis/AstraZeneca partnership provides commercial scale that Amarin lacks in international markets.

Emerging players

  • NewAmsterdam Pharma: Late-stage clinical biotech developing obicetrapib, an oral CETP inhibitor for dyslipidemia. Targeting statin-treated patients with elevated CV risk — directly overlapping with Amarin's prescriber base and patient population in CV risk reduction.
  • Arrowhead Pharmaceuticals: Clinical-stage company developing RNA interference therapeutics for cardiovascular and metabolic diseases, including plozasiran (APOC3) targeting severe hypertriglyceridemia. Competes in the same triglyceride-driven CV space as icosapent ethyl.
  • Madrigal Pharmaceuticals: Specialty pharma with Rezdiffra (resmetirom) approved for MASH/NASH with significant fibrosis. Cardiovascular/metabolic specialty focus with overlapping physician call points in endocrinology and cardiology practices.
  • Viking Therapeutics: Clinical-stage biotech developing metabolic and cardiovascular therapies, including VK2735 for obesity and oral formulations targeting cardiometabolic disease. Emerging competitor in adjacent CV/metabolic therapeutic categories.

Broad incumbents

  • Amgen: Global biopharmaceutical incumbent with Repatha (evolocumab), a leading PCSK9 inhibitor for LDL-C lowering. Competes with Amarin in cardiovascular lipid management through different mechanism but overlapping prescriber base and patient population.
  • Novartis: Large incumbent with Leqvio (inclisiran), an siRNA therapy for LDL-C lowering in cardiovascular patients. Represents a meaningful alternative therapeutic approach in the lipid management space where Amarin competes for prescriber attention and guideline inclusion.
  • Sanofi: Global pharma incumbent with Praluent (alirocumab, partnered with Regeneron), a PCSK9 inhibitor. Competes in cardiovascular lipid management with established cardiology commercial infrastructure across all major markets including Europe and Asia.
  • Pfizer: Largest pharmaceutical incumbent with legacy Lipitor franchise and broader cardiovascular portfolio. Provides scale benchmark and potential acquirer profile, while competing in the broader lipid management and CV risk reduction market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Amarin social profiles

Digital presence

Amarin financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amarin leadership team

Management profile

Number of profiles

Profiles6 records

Amarin funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amarin M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amarin

What does Amarin do?

Amarin develops, manufactures, and commercializes VASCEPA/VAZKEPA (icosapent ethyl), a prescription-only omega-3 fatty acid (EPA) therapy approved as an adjunct to statin therapy to reduce cardiovascular events in high-risk patients with elevated triglycerides, and as adjunct to diet for severe hypertriglyceridemia. The company sells directly in the U.S. and through regional commercial partners across approximately 100 international markets.

Is Amarin a public or private company?

Amarin is a public company. It is classified as public and is currently operating.

When was Amarin founded?

Amarin was founded in 1989. It employs 251 to 500 people.

Where is Amarin based?

Amarin is headquartered in Ballsbridge, Ireland, in the Europe region.

How does Amarin make money?

Four revenue lines are on record. Product Sales - United States are the primary driver. The others are product Revenue - Europe, licensing and Royalties and product Revenue - Rest of World.

Who are Amarin's main competitors?

Direct peers on record are Esperion Therapeutics and Ionis Pharmaceuticals. Emerging players are NewAmsterdam Pharma, Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals and Viking Therapeutics. Broad incumbents are Amgen, Novartis, Sanofi and Pfizer.

Does Amarin have an API?

No public API is recorded for Amarin.

What industry is Amarin in?

Amarin's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of AFAJAKAC, Omega-3 & Specialty Lipids (Fish/Algal Oils, EPA/DHA, MCTs, CLA, Phospholipids). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DrugPatentWatchMethod-of-Use Patents Only Work If Nobody Reads the Label CarefullyThe Supreme Court unanimously dismissed Amarin's inducement claim against Hikma, ruling that a generic's skinny label alone does not constitute active encouragement of a patented use. The court held that Hikma made no affirmative steps to encourage the cardiovascular indication, which accounted for over 75% of Vascepa sales.The Motley FoolAmarin: 3 Key Takeaways for Long-Term InvestorsAmarin returned to profitability in Q3 2026 after restructuring, generating $9 million in operating cash flow and $245,000 net income. Its European partner Recordati drove a 68% rise in in-market demand for VAZKEPA, and a phase III trial showed a 32% lower hazard of death in colorectal cancer patients. The company plans to evaluate capital deployment options.American Banking and Market NewsAmneal Pharmaceuticals (NASDAQ:AMRX) and Amarin (NASDAQ:AMRN) Financial ContrastAmarin and Amneal Pharmaceuticals are compared on profitability, valuation, and analyst ratings. Amneal has higher revenue ($3.20B vs $213.65M) and earnings, while Amarin trades at a lower P/E. Analysts favor Amneal with a higher consensus rating and upside.American Banking and Market NewsAmarin (NASDAQ:AMRN) Downgraded by Wall Street Zen to HoldWall Street Zen downgraded Amarin from Buy to Hold, while the stock opened at $11.61. The company reported Q3 EPS of $0.01, beating the -$0.10 consensus, but revenue of $39.55M missed the $43.76M estimate. Analysts forecast a -0.85 EPS for the current year.American Banking and Market NewsCritical Contrast: Organon & Co. (NYSE:OGN) vs. Amarin (NASDAQ:AMRN)Organon & Co. beats Amarin on 9 of 14 factors, including higher revenue ($6.22B vs $213.65M) and net margins (3.41% vs -10.87%). Amarin has a stronger consensus rating and higher upside, while Organon has higher institutional ownership.MarketBeatAmarin (NASDAQ:AMRN) Upgraded to "Buy" at Wall Street ZenWall Street Zen upgraded Amarin from Hold to Buy. The company reported Q3 EPS of $0.08, beating estimates of -$0.10, but revenue of $39.55M missed the $43.76M estimate. Analysts forecast a fiscal-year EPS of -$0.85.American Banking and Market NewsAmarin (NASDAQ:AMRN) Raised to “Buy” at Wall Street ZenWall Street Zen upgraded Amarin to a Buy rating, while other analysts have mixed ratings. The stock opened at $12.07, and the company reported Q2 EPS of $0.08, beating estimates of -$0.10. Analysts forecast a -0.85 EPS for the current year.MarketBeatAmarin (NASDAQ:AMRN) Announces Quarterly Earnings Results, Beats Estimates By $0.11 EPSAmarin reported Q3 EPS of $0.01, beating estimates by $0.11, but revenue fell to $39.55 million from $49.7 million. The company posted its first profitable quarter in two years with $245,000 net income and $9 million operating cash flow. Management expects pricing pressure to continue into 2027.Ticker ReportWhat Amarin (AMRN) Said on Its Q3 Earnings CallAmarin reported its first profitable quarter in two years for Q3 2026, with net income of $245,000 and operating cash flow of $9 million. Net revenue fell to $39.6 million from $49.7 million, driven by U.S. pricing pressure, while international in-market demand rose 59%.MarketBeatWhat Amarin (AMRN) Said on Its Q3 Earnings CallAmarin reported its first profitable quarter in two years for Q3 2026, with net income of $245,000 and operating cash flow of $9 million. Net revenue fell to $39.6 million from $49.7 million, driven by U.S. pricing pressure, while international in-market demand rose 59%. The company expects to retain exclusivity through 2026.